Cell-Permeating α -Ketoglutarate Derivatives Alleviate Pseudohypoxia in Succinate Dehydrogenase-Deficient Cells
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Succinate dehydrogenase (SDH) and fumarate hydratase (FH) are components of the tricarboxylic acid (TCA) cycle and tumor suppressors. Loss of SDH or FH induces pseudohypoxia, a major tumor-supporting event, which is the activation of hypoxia-inducible factor (HIF) under normoxia. In SDH- or FH-deficient cells, HIF activation is due to HIF1alpha stabilization by succinate or fumarate, respectively, either of which, when in excess, inhibits HIFalpha prolyl hydroxylase (PHD). To reactivate PHD, we focused on its substrate, alpha-ketoglutarate. We designed and synthesized cell-permeating alpha-ketoglutarate derivatives, which build up rapidly and preferentially in cells with a dysfunctional TCA cycle. This study shows that succinate- or fumarate-mediated inhibition of PHD is competitive and is reversed by pharmacologically elevating intracellular alpha-ketoglutarate. Introduction of alpha-ketoglutarate derivatives restores normal PHD activity and HIF1alpha levels to SDH-suppressed cells, indicating new therapy possibilities for the cancers associated with TCA cycle dysfunction.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Affected cells accumulate high levels of fumarate or succinate, and manifest HIFα upregulation that can be corrected by exogenous 2-oxoglutarate (MacKenzie et al., 2007), supporting a mechanistic link through competitive inhibition of the PHDs.”
From Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. (2008) · cites this paper as MacKenzie et al., 2007
In the citing paper
“To date, the clearest evidence that metabolites modulate HIF signaling comes from cells that are genetically defective in fumarate hydratase (FH) (Isaacs et al., 2005) or succinate hydrogenase (SDH; subunits b, c, and d) (MacKenzie et al., 2007; Pollard et al., 2005; Selak et al., 2005).”
From Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. (2008) · cites this paper as MacKenzie et al., 2007
In the citing paper
“Beyond VHL disease, deficiencies in mitochondrial Krebs cycle enzymes, including succinate dehydrogenase and fumarate hydratase, promote accumulation of metabolites that inhibit PHDs, consequently facilitating HIF-α accumulation [228,229].”
From HIF inhibition: Current strategies and clinical challenges (2026) · cites this paper as [228]
In the citing paper
“In fact, the latter, at least in the context of SDH loss, can be reversed by the addition of a membrane-permeable form of α-ketoglutarate (MacKenzie et al., 2007).”
From The emerging hallmarks of cancer metabolism (2016) · cites this paper as MacKenzie et al., 2007
Citations
Cites
Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase
Selak, M. A., Armour, S. M., MacKenzie, E. D., Boulahbel, H., Watson, D. G., Mansfield, K. D., Pan, Y., Simon, M. C., Thompson, C. B., & Gottlieb, E. (2005) · Cancer Cell · doi:10.1016/j.ccr.2004.11.022 · Cited by 2,108
Oxygen sensing by HIF hydroxylases
Schofield, C. J., & Ratcliffe, P. J. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1366 · Cited by 2,068 · cited 2×
“PHDs hydroxylate proline residues on the oxygen-dependent degradation (ODD) domain of HIF , generating docking sites for pVHL—part of an E3 ubiquitin ligase complex that targets HIF for degradation (21, 22).”
BackgroundTIGAR, a p53-Inducible Regulator of Glycolysis and Apoptosis
Bensaad, K., Tsuruta, A., Selak, M. A., Vidal, M. N. C., Nakano, K., Bartrons, R., Gottlieb, E., & Vousden, K. H. (2006) · Cell · doi:10.1016/j.cell.2006.05.036 · Cited by 2,019 · cited 1×
“from the rate for converting [5-(3)H]glucose to (3)H2O, as previously described (3), without a glucose starvation step.”
MethodSelf-citationHIF-1 and tumor progression: pathophysiology and therapeutics
Semenza, G. L. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02317-1 · Cited by 1,060 · cited 1×
“Under normal oxygenation conditions (normoxia), hypoxiainducible factor alpha (HIF ) proteins (HIF1 and/or HIF2 ), which are the formation-limiting units of the HIF transcription factor heteromer, are constantly both synthesized and degraded, a process that maintains them in high availability but at a very low steady…”
BackgroundIsaacs, J. S., Jung, Y. J., Mole, D. R., Lee, S., Torres-Cabala, C., Chung, Y.-L., Merino, M., Trepel, J., Zbar, B., Toro, J., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.06.017 · Cited by 958 · cited 1×
“Moreover, it was suggested that, in vitro, fumarate is a better inhibitor of PHD than succinate ( 13 ).”
BackgroundRole of VHL Gene Mutation in Human Cancer
Kim, W. Y., & Kaelin, W. G. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.061 · Cited by 943 · cited 1×
“Pseudohypoxia is probably a major cause of tumors associated with VHL mutations (15).”
BackgroundArchitecture of succinate dehydrogenase and reactive oxygen species generation
Yankovskaya, V., Horsefield, R., Törnroth, S., Luna-Chavez, C., Miyoshi, H., Léger, C., Byrne, B., Cecchini, G., & Iwata, S. (2003) · Science · doi:10.1126/science.1079605 · Cited by 927 · cited 1×
“The first suggested that reactive oxygen species (ROS) from an impaired complex II of the electron transport chain (18, 30) potentially inhibit PHDs (7).”
BackgroundPollard, P. J., Brière, J. J., Alam, N. A., Barwell, J., Barclay, E., Wortham, N. C., Hunt, T., Mitchell, M., Olpin, S., Moat, S. J., et al. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi227 · Cited by 865 · cited 1×
“Pseudohypoxia was also shown recently in tumor cells with mutations in fumarate hydratase (FH) or in any of three of the four subunits of succinate dehydrogenase (SDH), SDHB, SDHC, or SDHD (5, 8, 9, 19, 20 , 28).”
BackgroundCharacterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor
Hirsilä, M., Koivunen, P., Günzler, V., Kivirikko, K. I., & Myllyharju, J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m304982200 · Cited by 794 · cited 1×
“Although PHDs depend on oxygen for activity, their affinity for oxygen is low (Km 230 to 250 M), making them good oxygen sensors (11).”
BackgroundSuccinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer
King, A., Selak, M. A., & Gottlieb, E. (2006) · Oncogene · doi:10.1038/sj.onc.1209594 · Cited by 672 · cited 2×
“This possibility has far-reaching consequences, since pseudohypoxia due to mTor-mediated increased translation of HIF1 has been associated with several other tumors (16).”
BackgroundSelf-citation
Cited by
Items 301–360 of 360
Zhou, X., Zheng, M., Zhao, N., Hu, Y., Yang, K., Huo, J., Liu, G., Huang, J., Chen, L., Zhou, Y., et al. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105569 · Cited by 4
Greilberger, J., Erlbacher, K., Stiegler, P., Wintersteiger, R., & Herwig, R. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45080410 · Cited by 4
“Furthermore, exogenously administered aKG [28] could reverse the inhibition of PDH, a component of the HIF-1 pathway, caused by succinate and fumarate.”
BackgroundHIF inhibition: Current strategies and clinical challenges
Więch-Walów, A., Bartoszewska, S., Barton, A., Czechowicz, P., Dudzik, J., Wielockx, B., Collawn, J. F., & Bartoszewski, R. (2026) · Redox biology · doi:10.1016/j.redox.2026.104220 · Cited by 3
“Beyond VHL disease, deficiencies in mitochondrial Krebs cycle enzymes, including succinate dehydrogenase and fumarate hydratase, promote accumulation of metabolites that inhibit PHDs, consequently facilitating HIF-α accumulation [228,229].”
Xian, J., Pan, X., Kang, Y., Zheng, L., Yin, X., Zhang, M., Wei, Y., Tan, J., Zhang, M., Nie, L., et al. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-03195-y · Cited by 3
Cytoprotective Action of Sodium Fumarate in an in vitro Model of Hypoxia Using Sodium Dithionite
Vinokurov, A. Y., Popov, S. V., Belyakov, D. Y., Popov, D. Y., Nikulin, A. S., Zakrzhevskaya, V. D., Guseinov, R. G., Сивак, К. В., Dunaev, A., Potapova, E. V., et al. (2025) · Современные технологии в медицине · doi:10.17691/stm2025.17.1.09 · Cited by 3
Fumarate in the Preservation Solution Aggravates Chronic Allograft Nephropathy
Ploetz, C. J., Janßen, H., Zakrzewicz, A., Paddenberg, R., Padberg, W. M., Kummer, W., & Grau, V. (2009) · Journal of Surgical Research · doi:10.1016/j.jss.2009.05.044 · Cited by 3
Restraining colorectal cancer with αKG
Krauß, D., & Gottlieb, E. (2020) · Nature Cancer · doi:10.1038/s43018-020-0044-4 · Cited by 3
Gaunt, A. P., Lewis, J. S., Hesse, F., Cheng, T., Marco‐Rius, I., Brindle, K. M., & Comment, A. (2021) · Angewandte Chemie · doi:10.1002/ange.202112982 · Cited by 3
Allele-Specific Chemical Rescue of Histone Demethylases Using Abiotic Cofactors
Scott, V., Dey, D., Kuwik, J., Hinkelman, K., Waldman, M., & Islam, K. (2021) · ACS Chemical Biology · doi:10.1021/acschembio.1c00335 · Cited by 4
Paddenberg, R., Howold, N., Hoger, C., Janßen, H., Grau, V., & Kummer, W. (2009) · Cell Biochemistry and Function · doi:10.1002/cbf.1608 · Cited by 4
Misregulation of DNA Methylation Regulators in Cancer
Thompson, J. J., & Robertson, K. D. (2017) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-59786-7_5 · Cited by 3
Scantamburlo, F., Rubini, A., Toffanin, M., Castorina, M. E., Ciscato, F., Tomasoni, S., Finotti, P., Verin, R., Zappulli, V., Fantuz, M., et al. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03525-1 · Cited by 2
Yu, X., Lei, J., Du, X., He, Y., Peng, W., Yang, R., & He, F. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000003801 · Cited by 2
Carbone, F. P., Hanau, S., & Bianchi, N. (2026) · Non-Coding RNA · doi:10.3390/ncrna12020011 · Cited by 4
“Loss-or gain-of-function mutations in these enzymes alter TCA cycle activity, thereby promoting a metabolic reprogramming characterized by increased glycolytic dependence [133,134].”
Multiple Cutaneous and Uterine Leiomyomatosis
Makino, T. (2013) · InTech eBooks · doi:10.5772/53601 · Cited by 2
Kuwik, J., Scott, V., Chedid, S., Stransky, S., Hinkelman, K., Kavoosi, S., Calderon, M. J., Watkins, S. C., Sidoli, S., & Islam, K. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.4c13870 · Cited by 3
Angiogenesis, Arteriogenesis, and Mitochondrial Dysfunction
McMurtry, M. S. (2013) · Springer eBooks · doi:10.1007/978-1-4614-5930-9_15 · Cited by 2
Dysfunction of Mitochondrial ATP Production As a Target for Personalized Cancer Therapy
Tsuneoka, M., Teye, K., Okamoto, K., & Tanaka, Y. (2009) · Current pharmacogenomics and personalized medicine (Online)/Current pharmacogenomics and personalized medicine · doi:10.2174/187569209787582358 · Cited by 2
The Electron Transport Chain and Carcinogenesis
Brière, J.-J., Bénit, P., & Rustin, P. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-435-3_2 · Cited by 3
“Noticeably, other structurally related organic acids can also inhibit PHD [39].”
BackgroundMitochondria as Targets for Cancer Therapy
Ralph, S. J., & Neužil, J. (2008) · Springer eBooks · doi:10.1007/978-0-387-84835-8_12 · Cited by 3
MOLECULAR AND CLINICAL CHARACTERISTICS OF TRICARBOXYLIC ACID CYCLE-ASSOCIATED TUMORS
Lehtonen, H. J. (2008) · Helda - University of Helsinki Institutional Repository · Cited by 2
Nielsen, L. E. (2010) · Iowa State University Digital Repository (Iowa State University) · doi:10.31274/etd-180810-1455 · Cited by 4
Coutinho, L. L., Palmieri, E. M., Ridnour, L. A., Cheng, R. Y. S., Heinz, W. F., Anderson, S. K., Billiar, T. R., Chang, J. C., Lockett, S., Rangel, M. C., et al. (2026) · Redox Biology · doi:10.1016/j.redox.2026.104245 · Cited by 4
Reciprocal Crosstalk Between Angiogenesis and Metabolism
Laurent, G., & Mechta‐Grigoriou, F. (2014) · Springer eBooks · doi:10.1007/978-2-8178-0466-8_10 · Cited by 1
The emerging genetic landscape of renal cell carcinoma
Lee, G., Shinder, B. M., Sadimin, E. T., Stephenson, R. D., & Singer, E. A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-822824-1.00035-3 · Cited by 1
Sheng, X., & Wang, Y. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.4167 · Cited by 1
“These two biomarkers have also been reported in previous studies (56,57); however, they cannot be verified as biomarkers for mitochondrial metabolic disorders in the present study, due to the limited number of cases (n=31).”
Metabolic approaches to breast cancer treatment and prevention
Howell, A. (2007) · Breast Cancer Research · doi:10.1186/bcr1825 · Cited by 1
“Inhibition of lactate dehydrogenase activity by small interfering RNA [18] or of PDK by 2-chloroacetate stimulates mitochondrial activity [19] and is associated with inhibition of tumour cell growth or direct stimulation of TCA cycle activity using cell-permeating α-ketoglutarate [ 20 ].”
MethodPuertas-Frias, G., Saucedo-Rodríguez, M. J., Čunátová, K., Alán, L., Hrbac, P., Knězů, M., Konickova, S., Schimmer, J., Krakovkova, M., Vrbacký, M., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.14.682423 · Cited by 1
Regulation of Oxygen Homeostasis by Prolyl Hydroxylase Domains
Takeda, K., & Fong, G. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-857-7_22
Smith, G. (2015) · Enlighten: Theses (The University of Glasgow)
Mitochondrial Complex II in Cancer
Kľučková, K., Neužil, J., & Rohlena, J. (2014) · Springer eBooks · doi:10.1007/978-94-017-8984-4_4
Mitochondria : a target for anticancer therapy
Kruspig, B. (2014) · Figshare
The stem cell vascular niche in brain tumorigenesis
Tse, V., & Babu, H. (2011) · Cureus · doi:10.7759/cureus.37
“These inhibited mitochondria in tumor cells transmit pseudo hypoxic redox signals and activate HIF-1a even during normoxia [58].”
BackgroundBonventre, J. A. (2012) · Rutgers University Community Repository (Rutgers University) · doi:10.7282/t33f4nfq
Cutaneous Hamartoneoplastic Disorders
Nathanson, K. L. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-383834-6.00178-6
The Emerging Genetic Landscape in Renal Cell Carcinoma
Willoughby, K., & Drabkin, H. A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800886-7.00029-7
Greim, H. A., Hartwig, A., & MAK Commission (2016) · Wiley eBooks · doi:10.1002/3527600418.mbphaeoe4916
Philip, B. (2014) · Griffith Research Online · doi:10.25904/1912/1367
Zhao, F. L. (2014) · UA Campus Repository (The University of Arizona)
Philippou, E. (2016) · CRC Press eBooks · doi:10.1201/9781315371764-12
Rouse, B. T. (2013) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.717996838.793474112
Phäochromozytome [MAK Value Documentation in German language, 2010]
Arbeitsstoffe, D. F. S. S. Z. P. G., & Hartwig, A. (2012) · Wiley eBooks · doi:10.1002/3527600418.mbphaeod0049
Tumor hypoxia promotes MAPK signaling by inhibiting prolyl hydroxylation of SOS1Preprint
Yuan, L., Lv, G., Chen, H., Ren, C., Ye, Q., Li, H., Kong, X., Li, X., Cao, X., Zhang, J., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2335453/v1 · Cited by 1
Succinate as an Oncometabolite in Endocrine, Mesenchymal, and Epithelial Tumors
Yazdi, S. A. M., & Nazar, E. (2022) · Iranian Red Crescent Medical Journal · doi:10.32592/ircmj.2022.24.12.2395
GOT1 primes the cellular response to hypoxia by supporting glycolysis and HIF1α stabilisationPreprint
Grimm, F., Asuaje, A., Jain, A., dos Santos, M. S., Kleinjung, J., Nunes, P. M., Gehrig, S. M., Fets, L., MacRae, J. I., & Anastasiou, D. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.06.556522
Nakamura, K., Kohrogi, R., Shimamoto, S., Katafuchi, A., Nakashima, K., Tomonaga, S., Ohtsuka, A., & Ijiri, D. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.150843
Sencha, L. M., Karpova, M. A., Dobrynina, O. E., & Balalaeva, I. V. (2025) · Tissue and Cell · doi:10.1016/j.tice.2024.102719
He, T., Zeng, Y., Zhou, J., Tian, Y., Wang, D., Ma, J., Liu, J., Wu, W., Wei, C., & Jiao, R. (2026) · Cell Reports · doi:10.1016/j.celrep.2025.116922
Case Report: The silent giant: biochemical-clinical dissociation in a large cystic pheochromocytoma
Zhang, J., Zhao, Q., Wang, J., Yang, X., & Huang, S. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1770384
Deciphering the metabolic bases of Drosophila intestinal tumors
Delamotte, P. (2024) · theses.fr (ABES) · doi:10.70675/c62595f4zbfe2z4ee5zba1az272c10f57e2a
Han, X., Zheng, A., Du, P., Wang, Y., Li, Z., Hu, Y., Gao, F., Li, M., Guo, J., & Ma, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1826087 · Cited by 1
Oxidative stress and signaling in renal physiology and kidney diseases
Bhattarai, M., Maity, S., & Sharma, K. (2026) · Elsevier eBooks · doi:10.1016/b978-0-12-815389-5.00014-9
Kordana, N. E., Johnson, A., Puerner, C. T. S., Jones, J. T., Kowalski, C. H., Quinn, K. G., Liu, K.-W., Mauff, F. L., & Cramer, R. A. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.17.732805
Sun, X., Zhou, Q., Wu, Y., Qian, W., Ma, J., & Zhang, T. (2026) · Cellular Signalling · doi:10.1016/j.cellsig.2026.112686 · Cited by 1
Breast cancer stem cells across subtypes: Biology, challenges, and recent advances
Qayoom, H., Khan, R., Ji, A., Jabeen, A., & Mir, M. F. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-49109-2.00009-2
Li, M., & Mailloux, R. J. (2026) · Journal of Cellular Biochemistry · doi:10.1002/jcb.70104
Leng, H., Zheng, Z., Li, R., Yuan, Q., Lv, S., Yan, D., & Wu, L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1946009
Metadata
- Authors
- MacKenzie, E. D., Selak, M. A., Tennant, D. A., Payne, L. J., Crosby, S., Frederiksen, C. M., Watson, D. G., & Gottlieb, E.
- Affiliations
- Cancer Research UK (GB)
- Tocris Cookson Ltd, Northpoint, Fourth Way, Avonmouth, Bristol BS11 8TA, United Kingdom
- University of Strathclyde (GB)
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 2007-05-01
- Volume
- 27
- Issue
- 9
- Pages
- 3282-3289
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- PMC
- PMC1899954
- OpenAlex
- W2130757625
- Cited by
- 359
- References
- 31
- Citations by year
- 2026: 14 · 2025: 16 · 2024: 8 · 2023: 16 · 2022: 10 · 2021: 30 · 2020: 23 · 2019: 19 · 2018: 18 · 2017: 16 · 2016: 22 · 2015: 18 · 2014: 23 · 2013: 23 · 2012: 16
- FWCI
- 8.22
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Molecular and Cellular Biology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Funders
- Cancer Research UK
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Biochemical Acid Research Studies
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Keywords
- succinate dehydrogenase deficiency, fumarate hydratase deficiency, pseudohypoxia, hypoxia-inducible factor-1α, prolyl hydroxylase inhibition, cancer therapy, succinic acid, fumarate
- MeSH terms
- Cell Line, Cell Membrane Permeability, Humans, Ketoglutaric Acids, Protein Binding, Succinate Dehydrogenase, Molecular Structure, Cell Hypoxia, Ubiquitin, Proteasome Endopeptidase Complex, Hypoxia-Inducible Factor 1, alpha Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.